Zacks Investment Research Healthcare News

This is selected healthcare news for Zacks Investment Research, which is filed under Capital Firms. There are 39.4K news items for this page. Zacks Investment Research is occasionally combined with Medical Device, Biotech and Medical Research in news items.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
12/6/2022 Syndax's (SNDX) Leukemia Drug Gets FDA Breakthrough Therapy Tag
... Monday following the announcement of the news. The stock has improved 16.2% so far this year against the industry's decline of 16.3%. Image Source: Zacks Investment Research The Breakthrough Therapy tag granted to revumenib was based on data from the phase I AUGMENT-101 study. Data from the same ...
Nasdaq
12/6/2022 Should Investors Buy Pfizer (PFE) & Moderna (MRNA) Stock for 2023?
... Moderna's -31%. Over the last three years to cover the pandemic timeframe, MRNA is up +820% to crush PFE and the benchmark. Image Source: Zacks Investment Research Pfizer and Moderna stocks are gaining nice momentum as we close out the year. In fact, in the last three months, MRNA ...
Nasdaq
12/6/2022 Should Investors Buy Pfizer (PFE) & Moderna (MRNA) Stock for 2023?
... Moderna's -31%. Over the last three years to cover the pandemic timeframe, MRNA is up +820% to crush PFE and the benchmark. Image Source: Zacks Investment Research Pfizer and Moderna stocks are gaining nice momentum as we close out the year. In fact, in the last three months, MRNA ...
access-wallstreet.com
12/5/2022 BEAM Up as FDA Lifts Clinical Hold on the IND for BEAM-201
... following the announcement of the news. The stock has plunged 41.2% so far this year compared with the industry's decline of 16.2%. Image Source: Zacks Investment Research BEAM-201 is a potent and specific anti-CD7, allogeneic chimeric antigen receptor T-cell development candidate, which is being developed for ...
Nasdaq
12/5/2022 BEAM Up as FDA Lifts Clinical Hold on the IND for BEAM-201 - December 5, 2022 - Zacks.com
... following the announcement of the news. The stock has plunged 41.2% so far this year compared with the industry 's decline of 16.2%. Image Source: Zacks Investment Research BEAM-201 is a potent and specific anti-CD7, allogeneic chimeric antigen receptor T-cell development candidate, which is being developed for ...
Zacks
12/5/2022 GSK's Myelofibrosis Candidate MAA Gets Accepted in Europe - December 5, 2022 - Zacks.com
... on Jun 16, 2023. GSK's stock has declined 35.9% this year so far compared with a decline of 16.7% for the industry . Image Source: Zacks Investment Research Momelotinib was added to GSK's hematology portfolio with the July acquisition of California-based cancer biotech, Sierra Oncology. The regulatory filings ...
Zacks
12/5/2022 3 Top-Ranked Companies With Supercharged Dividend Growth - December 5, 2022 - Zacks.com
... is a chart illustrating the year-to-date performance of all three stocks, with the S&P 500 blended in as a benchmark. Image Source: Zacks Investment Research On top of strong dividend growth, all three stocks have displayed remarkable relative strength in 2022, outperforming the general market handily. Let ...
Zacks
12/5/2022 3 Top-Ranked Companies With Supercharged Dividend Growth
... is a chart illustrating the year-to-date performance of all three stocks, with the S&P 500 blended in as a benchmark. Image Source: Zacks Investment Research On top of strong dividend growth, all three stocks have displayed remarkable relative strength in 2022, outperforming the general market handily. Let ...
access-wallstreet.com
12/3/2022 Should Investors Consider These 3 Low-Beta Stocks?
... is a chart illustrating the year-to-date performance of all three stocks, with the S&P 500 blended in as a benchmark. Image Source: Zacks Investment Research Let's take a deeper dive into each one. Merck & Co, Inc. Merck is a global healthcare company that delivers innovative health ...
access-wallstreet.com
12/3/2022 Should Investors Consider These 3 Low-Beta Stocks?
... is a chart illustrating the year-to-date performance of all three stocks, with the S&P 500 blended in as a benchmark. Image Source: Zacks Investment Research Let's take a deeper dive into each one. Merck & Co, Inc. Merck is a global healthcare company that delivers innovative health ...
Nasdaq
12/3/2022 latest news- Top Stock Reports for Apple, IBM and Elevance Health – Yahoo Finance breaking news
... with rising expenses The Zacks analyst worries about escalating fuel prices as they are likely to keep earnings under pressure. Want the latest recommendations from Zacks Investment Research? Today you can download 7 best stocks for the next 30 days. Click to get this free report Apple Inc. (AAPL): Free ...
sondakika-haberleri.net
12/2/2022 Zacks Investment Ideas feature highlights: McKesson, Cardinal Health and Super Micro Computer
... Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation. See Stocks Free Media Contact Zacks Investment Research 800-767-3771 ext. 9339 [email protected] https://www.zacks.com Past performance is no guarantee of future results. Inherent in any investment is the potential ...
Nasdaq
12/2/2022 Lincoln National (LNC) Strengthens Hospital Indemnity Solution
... boosted sales for Lincoln National. Shares of Lincoln National have lost 40.8% in a year compared with the industry's decline of 8%. Image Source: Zacks Investment Research Zacks Rank & Key Picks Lincoln National currently carries a Zacks Rank 3 (Hold). Some better-ranked stocks in the insurance space are ...
Nasdaq
12/2/2022 Top Stock Reports for Apple, IBM & Elevance Health
... than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Apple Inc. (AAPL): Free ...
access-wallstreet.com
12/2/2022 Lincoln National (LNC) Strengthens Hospital Indemnity Solution - December 2, 2022 - Zacks.com
... boosted sales for Lincoln National. Shares of Lincoln National have lost 40.8% in a year compared with the industry 's decline of 8%. Image Source: Zacks Investment Research Zacks Rank & Key Picks Lincoln National currently carries a Zacks Rank 3 (Hold). Some better-ranked stocks in the insurance space are ...
Zacks
12/2/2022 3 Companies That Recently Unveiled Fresh Repurchase Programs - December 2, 2022 - Zacks.com
... is a chart illustrating the year-to-date performance of all three stocks, with the S&P 500 blended in as a benchmark. Image Source: Zacks Investment Research Let's take a deeper dive into each one. Walmart Walmart's product offerings include almost everything from grocery to cosmetics, electronics ...
Zacks
12/2/2022 3 Companies That Recently Unveiled Fresh Repurchase Programs
... is a chart illustrating the year-to-date performance of all three stocks, with the S&P 500 blended in as a benchmark. Image Source: Zacks Investment Research Let's take a deeper dive into each one. Walmart Walmart's product offerings include almost everything from grocery to cosmetics, electronics ...
access-wallstreet.com
12/2/2022 Rigel (RIGL) Up on FDA Nod to Blood Cancer Drug Rezlidhia
... the announcement of the news. However, the stock has plunged 74.2% so far this year compared with the industry's decline of 28.6%. Image Source: Zacks Investment Research The FDA approval for Rezlidhia was based on data from the phase II registrational study, which evaluated Rezlidhia (150 mg) as a ...
Nasdaq
12/2/2022 Rigel (RIGL) Up on FDA Nod to Blood Cancer Drug Rezlidhia - December 2, 2022 - Zacks.com
... the announcement of the news. However, the stock has plunged 74.2% so far this year compared with the industry 's decline of 28.6%. Image Source: Zacks Investment Research The FDA approval for Rezlidhia was based on data from the phase II registrational study, which evaluated Rezlidhia (150 mg) as a ...
Zacks
12/2/2022 Oncolytics (ONCY) Up on Lead Drug Securing 2nd FDA Fast Track Tag - December 2, 2022 - Zacks.com
... designation is also eligible for rolling review. This year so far, shares of Oncolytics have surged 52.5% against the industry 's 18.3% fall. Image Source: Zacks Investment Research FDA granted the fast-track designation based on data from the phase I/II GOBLET study, which is evaluating pelareorep plus Roche ...
Zacks
12/1/2022 3 Stocks Silently Outperforming Energy in 2022 - December 1, 2022 - Zacks.com
... chart illustrating the year-to-date performance of all three stocks, with the Zacks Oils and Energy sector blended in as a benchmark. Image Source: Zacks Investment Research As we can see, all three stocks have outperformed the sector by fair margins (especially SMCI), entirely shrugging off the general market ...
Zacks
12/1/2022 Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
... more, on Zacks.com. Zacks Names "Single Best Pick to Double" Johnson & Johnson (JNJ) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research ...
Nasdaq
12/1/2022 Does Health Catalyst (HCAT) Have the Potential to Rally 61% as Wall Street Analysts Expect?
... good guide. Zacks Names "Single Best Pick to Double" Health Catalyst, Inc. (HCAT) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research ...
Nasdaq
12/1/2022 Sensata (ST) Unveils New Tire Mounted Sensor to Tap TPMS Market - December 1, 2022 - Zacks.com
... Zacks Rank 4 (Sell). Shares of the company have lost 21.6% compared with the industry's decline of 15.4% in the past year. Image Source: Zacks Investment Research Stocks to Consider Some better-ranked stocks from the broader technology space are Arista Networks ( ANET Quick Quote ANET - Free Report ) , Plexus ...
Zacks
11/30/2022 3 Top-Ranked Large-Caps With Big Growth
... is a chart illustrating the year-to-date performance of all three stocks, with the S&P 500 blended in as a benchmark. Image Source: Zacks Investment Research As we can see, on top of impressive growth profiles, all three stocks have witnessed positive momentum in 2022, outperforming the S ...
Nasdaq